secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262641
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology enters $330M upfront collaboration with Kyowa Kirin for ziftomenib; potential milestones up to $1.491B
--------------------------------------------------------------------------------

- Upfront payment of $330M to Kura; near-term milestones up to $420M including launch of monotherapy R/R setting.
- Additional milestones of $513M for hematologic malignancies, plus up to $228M if field expansion option for solid tumors is exercised.
- Kyowa Kirin to lead ex-US development/commercialization; Kura leads US with joint profit/cost sharing on US commercialization.
- Kura retains rights to next-generation menin inhibitors outside oncology field; exclusivity obligations for both parties.
- Tiered double-digit royalties on ex-US sales of ziftomenib on a country-by-country basis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524262641/0001193125-24-262641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312524262641/d902118d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer